|drug1538||Hydroxychloroquine Sulfate Wiki||0.29|
|D000013||Congenital Abnormalities NIH||0.71|
There is one clinical trial.
CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.
Description: Visual analysis of the pulmonary lobes by calculating a extent score for each patientMeasure: Visual analysis of pulmonary lobes Time: 1 day
Description: Measurement of metabolic activity with SUV max of lung areas with CT abnormalitiesMeasure: Measurement of metabolic activity Time: 1 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports